A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic properties

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 10, 2004, Pages 3944-3953

  Olsen, David B ^a   Eldrup, Anne B ^b   Bartholomew, Linda ^c   Bhat, Balkrishen ^b   Bosserman, Michele R ^a   Ceccacci, Alessandra ^c   Colwell, Lawrence F ^a   Fay, John F ^a   Flores, Osvaldo A ^a   Getty, Krista L ^a   Grobler, Jay A ^a   LaFemina, Robert L ^a   Markel, Eric J ^a   Migliaccio, Giovanni ^c   Prhavc, Marija ^b   Stahlhut, Mark W ^a   Tomassini, Joanne E ^a   MacCoss, Malcolm ^a   Hazuda, Daria J ^a   Carroll, Steven S ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b ISIS PHARMACEUTICALS   (United States)

^c IRBM   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2' C METHYLADENOSINE; 7 DEAZA 2' C METHYLADENOSINE; 7 DEAZA 2' C METHYLGUANINE; ACICLOVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; DIDANOSINE; GUANOSINE DERIVATIVE; RNA DIRECTED RNA POLYMERASE; TUBERCIDIN; TUBERCIDIN DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; CELL MEMBRANE PERMEABILITY; CHEMICAL MODIFICATION; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG LIVER LEVEL; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; ENZYME ASSAY; FEMALE; HEPATITIS C VIRUS; IC 50; LETHAL DOSE; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; REPLICON; VIRUS INHIBITION; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; CULTURE TECHNIQUES; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; JURKAT CELLS; LETHAL DOSE 50; MICE; POLYNUCLEOTIDE ADENYLYLTRANSFERASE; RNA; RNA POLYMERASE II; RNA REPLICASE; THYMIDINE; TUBERCIDIN; VIRUS REPLICATION;

EID: 4644257970     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.10.3944-3953.2004     Document Type: Article

References (35)

1. Abola, J., and M. Sundaralingam. 1973. Refinement of the crystal structure of tubercidin. Acta Crystallogr. B Struct. Crystallogr. Cryst. Chem. 29:697-703.
2. Acs, G., E. Reich, and M. Mori. 1964. Biological and biochemical properties of the analogue antibiotic tubercidin. Proc. Natl. Acad. Sci. USA 52:493-501.
3. Barnard, D. L., V. D. Stowell, K. L. Seley, V. R. Hegde, S. R. Das, V. P. Rajappan, S. W. Schneller, D. F. Smee, and R. W. Sidwell. 2001. Inhibition of measles virus replication by 5′-nor carbocyclic adenosine analogues. Antivir. Chem. Chemother. 12:241-250.
4. Behrens, S. E., L. Tomei, and R. De Francesco. 1996. Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus. EMBO J. 15:12-22.
5. Bloch, A., R. J. Leonard, and C. A. Nichol. 1967. On the mode of action of 7-deaza-adenosine (tubercidin). Biochim. Biophys. Acta 138:10-25.
6. Bonnin, A., J. M. Lazaro, L. Blanco, and M. Salas. 1999. A single tyrosine prevents insertion of ribonucleotides in the eukaryotic-type phi29 DNA polymerase. J. Mol. Biol. 290:241-251.
7. Boudou, V., L. Kerremans, B. De Bouvere, E. Lescrinier, G. Schepers, R. Busson, A. Van Aerschot, and P. Herdewijn. 1999. Base pairing of anhydrohexitol nucleosides with 2,6-diaminopurine, 5-methylcytosine and uracil as base moiety. Nucleic Acids Res. 27:1450-1456.
8. Carrasco, L., and D. Vazquez. 1984. Molecular bases for the action and selectivity of nucleoside antibiotics. Med. Res. Rev. 4:471-512.
9. Carroll, S. S., R. L. Lafemina, D. L. Hall, A. L. Himmelberger, L. C. Kuo, M. Maccoss, D. B. Olsen, C. A. Rutkowski, J. E. Tomassini, H. An, B. Bhat, N. Bhat, P. D. Cook, A. B. Eldrup, C. J. Guinosso, M. Prhavc, and T. P. Prakash. August 2002. Preparation of nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase. U.S. patent 6777395.
10. Carroll, S. S., V. Sardana, Z. Yang, A. R. Jacobs, C. Mizenko, D. Hall, L. Hill, J. Zugay-Murphy, and L. C. Kuo. 2000. Only a small fraction of purified hepatitis C RNA-dependent RNA polymerase is catalytically competent: implications for viral replication and in vitro assays. Biochemistry 39:8243-8249.
11. Carroll, S. S., J. E. Tomassini, M. Bosserman, K. Getty, M. W. Stahlhut, A. B. Eldrup, B. Bhat, D. Hall, A. L. Simcoe, R. LaFemina, C. A. Rutkowski, B. Wolanski, Z. Yang, G. Migliaccio, R. De Francesco, L. C. Kuo, M. MacCoss, and D. B. Olsen. 2003. Inhibition of hepatitis C virus RNA replication by 2′-modified nucleoside analogs. J. Biol. Chem. 278:11979-11984.
12. Centers for Disease Control and Prevention. 1998. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Morb. Mortal. Wkly. Rep. Recomm. Rep. 47:1-39.
13. Cory, A. H., V. Samano, M. J. Robins, and J. G. Cory. 1994. 2′-Deoxy-2′-methylene derivatives of adenosine, guanosine, tubercidin, cytidine and uridine as inhibitors of L1210 cell growth in culture. Biochem. Pharmacol. 47:365-371.
14. De Francesco, R., L. Tomei, S. Altamura, V. Summa, and G. Migliaccio. 2003. Approaching a new era for hepatitis C virus therapy: inhibitors of the NS3-4A serine protease and the NS5B RNA-dependent RNA polymerase. Antivir. Res. 58:1-16.
15. Division of Viral Hepatitis, National Center for Infectious Diseases, Centers for Disease Control and Prevention,. 2003. Viral hepatitis C: fact sheet. [Online.] www.cdc.gov/ncidod/diseases/hepatitis/c/fact.htm
16. Eldrup, A. B., C. R. Allerson, C. F. Bennett, S. Bera, B. Bhat, N. Bhat, M. R. Bosserman, J. Brooks, C. Burlein, S. S. Carroll, P. D. Cook, K. L. Getty, M. MacCoss, D. R. McMasters, D. B. Olsen, T. P. Prakash, M. Prhavc, Q. Song, J. E. Tomassini, and J. Xia. 2004. Structure-activity relationship of purine ribonucleosides for inhibition of hepatitis C virus RNA-dependent RNA polymerase. J. Med. Chem. 47:2283-2295.
17. Gardner, A. F., and W. E. Jack. 1999. Determinants of nucleotide sugar recognition in an archaeon DNA polymerase. Nucleic Acids Res. 27:2545-2553.
18. Ge, H., E. Martinez, C. M. Chiang, and R. G. Roeder. 1996. Activator-dependent transcription by mammalian RNA polymerase II: in vitro reconstitution with general transcription factors and cofactors. Methods Enzymol. 274:57-71.
19. Huffman, J. H., R. W. Sidwell, G. P. Khare, J. T. Witkowski, L. B. Allen, and R. K. Robins. 1973. In vitro effect of 1-beta-D-ribofuranosyl-1,2,4- triazole-3-carboxamide (virazole, ICN 1229) on deoxyribonucleic acid and ribonucleic acid viruses. Antimicrob. Agents Chemother. 3:235-241.
20. Koonin, E. V., and V. V. Dolja. 1993. Evolution and taxonomy of positive-strand RNA viruses: implications of comparative analysis of amino acid sequences. Crit. Rev. Biochem. Mol. Biol. 28:375-430.
21. Lauer, G. M., and B. D. Walker. 2001. Hepatitis C virus infection. N. Engl. J. Med. 345:41-52.
22. McFarlan, S. C., S. P. Ong, and H. P. Hogenkamp. 1996. Mechanism-based inhibition of ribonucleoside diphosphate reductase from Corynebacterium nephridii by 2′-C-methyladenosine diphosphate. Biochemistry 35:4485-4491.
23. Migliaccio, G., J. E. Tomassini, S. S. Carroll, L. Tomei, S. Altamura, B. Bhat, L. Bartholomew, M. R. Bosserman, A. Ceccacci, L. F. Colwell, R. Cortese, R. De Francesco, A. B. Eldrup, K. L. Getty, X. S. Hou, R. L. LaFemina, S. W. Ludmerer, M. MacCoss, D. R. McMasters, M. W. Stahlhut, D. B. Olsen, D. J. Hazuda, and O. A. Flores. 2003. Characterization of resistance to non-obligate chain terminating ribonucleoside analogs which inhibit HCV replication in vitro. J. Biol. Chem. 278:49164-49170.
24. Mottola, G., G. Cardinali, A. Ceccacci, C. Trozzi, L. Bartholomew, M. R. Torrisi, E. Pedrazzini, S. Bonatti, and G. Migliaccio. 2002. Hepatitis C virus nonstructural proteins are localized in a modified endoplasmic reticulum of cells expressing viral subgenomic replicons. Virology 293:31-43.
25. Poynard, T., M. F. Yuen, V. Ratziu, and C. L. Lai. 2003. Viral hepatitis C. Lancet 362:2095-2100.
26. Shiffman, M. L. 2003. Natural history and risk factors for progression of hepatitis C virus disease and development of hepatocellular cancer before liver transplantation. Liver Transpl. 9:S14-S20.
27. Sidwell, R. W., and J. H. Huffman. 1971. Use of disposable micro tissue culture plates for antiviral and interferon induction studies. Appl. Microbiol. 22:797-801.
28. Sidwell, R. W., J. H. Huffman, G. P. Khare, L. B. Allen, J. T. Witkowski, and R. K. Robins. 1972. Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science 177:705-706.
29. Smith, C. G., G. D. Gray, R. G. Carlson, and A. R. Hanze. 1967. Biochemical and biological studies with tubercidin (7-deaza-adenosine), 7-deazainosine and certain nucleotide derivatives of tubercidin. Adv. Enzyme Regul. 5:121-151.
30. Szabo, E., G. Lotz, C. Paska, A. Kiss, and Z. Schaff. 2003. Viral hepatitis: new data on hepatitis C infection. Pathol. Oncol. Res. 9:215-221.
31. Tomassini, J. E., E. Boots, L. Gan, P. Graham, V. Munshi, B. Wolanski, J. F. Fay, K. Getty, and R. LaFemina. 2003. An in vitro Flaviviridae replicase system capable of authentic RNA replication. Virology 313:274-285.
32. Tomei, L., S. Altamura, L. Bartholomew, M. Bisbocci, C. Bailey, M. Bosserman, A. Cellucci, E. Forte, I. Incitti, L. Orsatti, U. Koch, R. De Francesco, D. B. Olsen, S. S. Carroll, and G. Migliaccio. 2004. Characterization of the inhibition of hepatitis C virus RNA replication by nonnucleosides. J. Virol. 78:938-946.
33. Tomei, L., Sergio Altamura, Linda Bartholomew, Antonino Biroccio, Alessandra Ceccacci, Laura Pacini, Frank Narjes, Nadia Gennari, Monica Bisbocci, Ilario Incitti, Laura Orsatti, Steven Harper, Ian Stansfield, Michael Rowley, Raffaele De Francesco, and Giovanni Migliaccio. 2003. Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis C virus RNA dependent RNA polymerase. submitted to J. Virol. 77:13225-13231.
34. Trozzi, C., L. Bartholomew, A. Ceccacci, G. Biasiol, L. Pacini, S. Altamura, F. Narjes, E. Muraglia, G. Paonessa, U. Koch, R. De Francesco, C. Steinkuhler, and G. Migliaccio. 2003. In vitro selection and characterization of hepatitis C virus serine protease variants resistant to an active-site peptide inhibitor. J. Virol. 77:3669-3679.
35. Yang, G., M. Franklin, J. Li, T. C. Lin, and W. Konigsberg. 2002. A conserved Tyr residue is required for sugar selectivity in a Pol alpha DNA polymerase. Biochemistry 41:10256-10261.